Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2581 to 2595 of 8933 results

  1. Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]

    In development Reference number: GID-TA11516 Expected publication date:  06 May 2027

    Technology appraisal guidance
    In development

  2. Laparoscopic lumbar sympathectomy for foot hyperhidrosis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Cutting blocks for total knee arthroplasty

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. NPJ5008 for treating malignant hyperthermia [TSID11829]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Digital technologies delivering CBT for insomnia in adults

    In development Reference number: GID-HTE10068 Expected publication date:  06 January 2027

    Health technology evaluations
    In development

  6. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  29 July 2026

    NICE guideline
    In development

  7. Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

    In development Reference number: GID-TA10046 Expected publication date:  22 November 2017

    Technology appraisal guidance
    In development

  8. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development Reference number: GID-TA10994 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]

    Awaiting development Reference number: GID-TA11667 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]

    Awaiting development Reference number: GID-TA11534 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  12. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Tildrakizumab for treating active psoriatic arthritis [ID6724]

    Awaiting development Reference number: GID-TA11807 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development Reference number: GID-TA10911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment

    In development Reference number: GID-HTE10067 Expected publication date: TBC

    Health technology evaluations
    In development